Kemwell Biopharma, Bangalore
Bengaluru, India
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Kemwell Biopharma, Bangalore
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Bengaluru, India
- Modalities
- Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish, Lyophilized Drug Product
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Kemwell Biopharma, Bangalore
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish, Lyophilized Drug Product
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Broad modality coverage (7 modalities)
Recent News 10 articles
Cipla to form JV with Kemwell Biopharma; share price down marginally - Moneycontrol.com
Kemwell Biopharma Facility in Bengaluru Successfully Completes U.S. FDA Inspection for Commercial Drug-Product Manufacturing - Business Wire
Kemwell’s Bengaluru Facility Completes U.S. FDA Inspection - Contract Pharma
Cipla, Kemwell Biopharma, Manipal forge cell therapy alliance in US - Medical Dialogues
Kemwell Announces Successful U.S. FDA Inspection of its Bangalore, India Manufacturing Facility - BioProcess International
Cipla Forms 60:40 Joint Venture with Kemwell Biopharma for Biologics Development - scanx.trade
In $205 million deal, Recipharm buys Kemwell’s US, India CDMO businesses - BioPharma Dive
RevOpsis and Kemwell Biopharma Enter into Strategic Manufacturing Partnership to Expedite Development of Novel Multispecific Biologics - PR Newswire
Cipla JV with Manipal subsidiary and Kemwell Biopharma to develop cell therapy - The Times of India
Cipla, Kemwell Biopharma, Manipal Form Cell Therapy JV - Contract Pharma
Frequently Asked Questions About Kemwell Biopharma, Bangalore
What is Kemwell Biopharma, Bangalore's CDMO Signal Score?
Kemwell Biopharma, Bangalore has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Kemwell Biopharma, Bangalore for a manufacturing program?
Use the free AI matchmaker to compare Kemwell Biopharma, Bangalore against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Kemwell Biopharma
Bengaluru, India
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Biosimilars, Cell Therapy, Sterile Fill-Finish
Mabion S.A.
Konstantynów Łódźki, Poland
Monoclonal Antibody, Recombinant Protein, Biosimilars, Vaccine Antigens, ADC / PDC (analytics & development), Sterile Fill-Finish
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Antibody Fragments, Biosimilars, Biologics
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein